
ActoGeniX’s mission is to develop and commercialize innovative biological therapies, to improve the treatment and well-being of patients with gastrointestinal, immunological and metabolic diseases.
The Company was founded to address the growing need for more effective and safer medications in these important therapeutic areas. To achieve this ambitious goal, ActoGeniX has been applying its proprietary technology platform to create a rich pipeline of ActoBiotics™ .

ActoGeniX receives IWT grant for treatment of Clostridium difficile-associated enteric disease